**Rigel Pharmaceuticals Reports Increased Revenue Driven by Product Sales in 2025**

Rigel Pharmaceuticals Inc. (Nasdaq: RIGL), a biotechnology company focused on hematologic disorders and cancer, released its 10-K filing, detailing its financial performance and operational developments for the fiscal year 2025. The company reported total revenues of $294.3 million, a 64% increase compared to $179.3 million in 2024. This growth was primarily fueled by a significant rise in net product sales, which reached $232.0 million, up from $144.9 million in the previous year. Contract revenues from collaborations also contributed, increasing to $62.0 million from $34.4 million in 2024. The company's approximate aggregate market value of the Common Stock held by non-affiliates was $331.6 million as of June 30, 2025. As of February 25, 2026, there were 18,473,130 shares of the company’s common stock outstanding.

The company's revenue growth was attributed to increased sales of its key products. TAVALISSE, used for chronic immune thrombocytopenia (ITP), saw net product sales increase by 52% to $158.8 million, driven by higher quantities sold, a lower revenue reserves rate, and a higher price per bottle. REZLIDHIA, indicated for relapsed or refractory acute myeloid leukemia (AML), experienced a 35% increase in net product sales, reaching $31.0 million, due to increased quantities sold and a higher price per bottle, partially offset by a higher revenue reserves rate. GAVRETO, which Rigel began commercializing in June 2024, generated $42.1 million in net product sales in 2025, compared to $17.1 million in 2024.

Rigel continued to advance its clinical development programs, notably R289, a dual interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor. The company completed enrollment in the dose escalation part of a Phase 1b study evaluating R289 in patients with relapsed or refractory lower-risk myelodysplastic syndrome (MDS) in July 2025 and announced enrollment of the first patient in the dose expansion part of the study in October 2025. Initial data from the dose escalation part of the Phase 1b study was presented at the 66th and 67th American Society of Hematology (ASH) Annual Meeting and Exposition. The FDA granted R289 Orphan Drug designation for the treatment of myelodysplastic syndromes in January 2025 and Fast Track designation for the treatment of previously-treated transfusion dependent lower-risk myelodysplastic syndrome in November 2024.

Operationally, Rigel highlighted its strategic collaborations with the University of Texas MD Anderson Cancer Center (MDACC) and the Collaborative Network for Neuro-Oncology Clinical Trials (CONNECT) to expand the evaluation of olutasidenib in other disease areas with IDH1 mutations. The company also noted the ongoing Phase 2a/2b clinical trial of ocadusertib, a RIPK1 inhibitor being developed in collaboration with Eli Lilly and Company, for the treatment of rheumatoid arthritis. In March 2025, Rigel entered into a settlement agreement with Annora Pharma Private Ltd., Hetero Labs Ltd., and Hetero USA, Inc., resolving patent litigation related to TAVALISSE. Annora will have a license to sell its generic product in the second quarter of 2032 or earlier under certain circumstances.

About RIGEL PHARMACEUTICALS INC

Rigel Pharmaceuticals is a biotech company focused on developing therapies for hematologic disorders and cancer. Its core products include FDA-approved treatments for immune thrombocytopenia, AML with IDH1 mutations, and RET fusion-positive cancers. The company leverages strategic collaborations, licensing, and a commercial infrastructure to develop, manufacture, and market targeted therapies globally, emphasizing innovation in oncology and hematology.

This description was generated via AI from an annual report. Updated 8 months ago.

About 10-K Filings

A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.

Key points about the 10-K:

  • Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
  • Content: It includes:
    • Detailed financial statements audited by an independent accounting firm
    • Management's Discussion and Analysis (MD&A) of financial condition and results
    • Description of the company's business, properties, and legal proceedings
    • Risk factors and market risks
    • Executive compensation and corporate governance information
  • Importance: Considered the most comprehensive and important document a public company files with the SEC.
  • Length: Often exceeds 100 pages due to its extensive and detailed nature.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.